Analyst Optimism Persists Despite Insider Selling at Madrigal Analysts remain bullish on Madrigal Pharmaceuticals, maintaining strong buy ratings and high price targets, even as insider selling raises caution. Recent sales by top executives, including CEO William Sibold, have drawn attention, but the company’s robust clinical progress and revenue growth continue to support positive forecasts.34